A RISK-BENEFIT ASSESSMENT OF ZIDOVUDINE IN THE PREVENTION OF PERINATAL HIV TRANSMISSION

被引：20

作者：

NEWELL, ML

GIBB, DM

机构：

[1] Unit of Epidemiology and Biostatistics, Institute of Child Health, London, WC1N 1EH

来源：

DRUG SAFETY | 1995年 / 12卷 / 04期

关键词：

D O I：

10.2165/00002018-199512040-00007

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Mother-to-child transmission is the main mode of acquisition of HIV infection for children, and the estimated rate of vertical transmission ranges from 15 to 20% in Europe, 15 to 25% in the US and 25 to 35% in Africa. Vertical transmission is associated with clinical and immunological progression of disease in the mother, breastfeeding and possibly with vaginal delivery. Recently, the findings of the American/French AIDS Clinical Trial Group (ACTG) trial 076 showed that in women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, zidovudine (ZDV, 3'-azido-3'-droxy-thymidine, AZT) reduced the risk of vertical transmission when administered during pregnancy and delivery and to the infant in the first 6 weeks of life. No significant adverse effects were observed in either the mothers or neonates. Although the results of the American/French trial on the use of zidovudine to prevent vertical transmission are encouraging, many questions remain unanswered. The optimal timing of administration of zidovudine is unknown, as is its effectiveness in women with clinical characteristics that differ from those of the women in the trial. Concern has been expressed about the possibility of long term effects of exposure of zidovudine during pregnancy, both for the mother and the infant (of whom 4 out of 5 are uninfected anyway) and the implications for antenatal screening. Further trials with different zidovudine regimens and other strategies to prevent vertical transmission are being planned in several countries.

引用

页码：274 / 282

页数：9

共 43 条

[1]

Chin J., The growing impact of the HIV/AIDS pandemic on children born to HIV-infected women, Clin Perinatol, 21, pp. 1-14, (1994)

[2]

Dabis F., ellati P., Dunn D., Et al., Estimating the rate of mother-to-child transmission of HIV. Report of a workshop on methodological issues, Ghent (Belgium), 17–20 February 1992, AIDS, 7, (1993)

[3]

Newell M.L., Peckham C., Risk factors for vertical transmission of HIV-1 and early markers of HIV-1 infection in children, AIDS, 7, (1993)

[4]

Dunn D., Newell M., Ades A., Et al., Risk of human immunodeficiency virus type 1 transmission through breastfeeding, Lancet, 340, (1992)

[5]

Caesarean section and risk of vertical transmission of HIV-1 infection, Lancet, 343, (1994)

[6]

Dunn D.T., Newell M.L., Mayaux M.J., Et al., Mode of delivery and vertical transmission of HIV-1: a review of prospective studies, J Acquir Immune Defic Syndr, 7, (1994)

[7]

Newell M., Peckham C.S., Working towards a European strategy for intervention to reduce vertical transmission of HIV, Br J Obstet Gynaecol, 101, (1994)

[8]

Borkowsky W., Krasinski K., Perinatal human immunodeficiency virus infection: ruminations on mechanisms of transmission and methods of intervention, Pediatrics, 90, (1992)

[9]

Furman P.A., Fyfe J.A., St Clair M.H., Et al., Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase, Proc Natl Acad Sci USA, 83, (1986)

[10]

Yarchoan R., Mitsuya H., Meyers C., Et al., Clinical pharmacology of 3-azido-2 3-dideoxythymidine [zidovudine] and related dideoxynucleosides, N Engl J Med, 321, (1989)

← 1 2 3 4 5 →